On April 8, 1997, after buying the remaining % of Roussel-Uclaf stock in early 1997,  Hoechst AG ( US$30 (equivalent to $ in 2016) billion annual revenue) announced the end of its manufacture and sale of Mifegyne ( US$ (equivalent to $ in 2016) million annual revenue) and the transfer of all rights for medical uses of mifepristone outside of the United States to Exelgyn ., a new single-product company immune to antiabortion boycotts, whose CEO was former Roussel-Uclaf CEO Édouard Sakiz.  In 1999, Exelgyn won approval of Mifegyne in 11 additional countries, and in 28 more countries over the following decade. 
Trenbolone undecanoate , or trenbolone undecylate , is a synthetic and injected anabolic–androgenic steroid (AAS) and a derivative of nandrolone (19-nortestosterone) which was never marketed.   It is the C17β undecanoate (undecylate) ester and a long-acting prodrug of trenbolone .   The drug was described by Roussel Uclaf in 1967 and was the first long-lasting ester of trenbolone to be developed.   Subsequently, trenbolone hexahydrobenzylcarbonate , a roughly equivalent compound, was developed and introduced for use in humans in 1980, though it was discontinued in 1997.  Trenbolone enanthate is another long-lasting ester of trenbolone.  Similarly to trenbolone undecanoate, it was never marketed, but it has been sold on the black market as a designer steroid for bodybuilders and athletes .